HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

YM-254890

structure in first source

Also Known As:

YM254890

Networked: 12 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - YM-254890: 12
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cyclic Peptides: 530
    - YM-254890: 12

Experts

1.	Taniguchi, Masatoshi: 5 articles (05/2006 - 09/2003)
2.	Kawasaki, Tomihisa: 4 articles (05/2006 - 09/2003)
3.	Hayashi, Kazumi: 3 articles (05/2006 - 09/2003)
4.	Moritani, Yumiko: 3 articles (05/2006 - 09/2003)
5.	Saito, Tetsu: 3 articles (05/2006 - 09/2003)
6.	Takasaki, Jun: 3 articles (05/2006 - 09/2003)
7.	Uemura, Toshio: 3 articles (05/2006 - 07/2005)
8.	Miyata, Keiji: 2 articles (05/2006 - 04/2006)
9.	Uchida, Wataru: 2 articles (05/2006 - 04/2006)
10.	Takamatsu, Hajime: 2 articles (04/2006 - 07/2005)

Related Diseases

1.	Thrombosis (Thrombus) 09/01/2003 - "Antithrombotic and thrombolytic efficacy of YM-254890, a G q/11 inhibitor, in a rat model of arterial thrombosis." 05/01/2006 - "The intravenous bolus injection of YM-254890 dose dependently inhibited recurrent thrombosis without affecting systemic blood pressure or prolonging template bleeding time. " 05/01/2006 - "1 The effects of YM-254890, a specific Galpha(q/11) inhibitor, on platelet functions, thrombus formation under high-shear rate condition and femoral artery thrombosis in cynomolgus monkeys were investigated. " 05/01/2006 - "Biological properties of a specific Galpha q/11 inhibitor, YM-254890, on platelet functions and thrombus formation under high-shear stress." 07/01/2005 - "However, YM-254890 significantly reduced systemic blood pressure at doses 3 times higher than those that produced significant inhibitory effects on thrombosis and neointima formation. "
2.	Uveal melanoma 01/01/2021 - "In vivo, YM-254890 slowed tumor growth but did not cause regression in human uveal melanoma xenografts. " 11/03/2023 - "In this study, we treated GNAQ-mutant uveal melanoma cell lines with a Gαq/11 inhibitor, YM-254890, and conducted a kinase signaling proteomic screen using multiplexed-kinase inhibitors followed by mass spectrometry. "
3.	Neoplasms (Cancer) 01/01/2021 - "In vivo, YM-254890 slowed tumor growth but did not cause regression in human uveal melanoma xenografts. " 01/01/2023 - "We further demonstrate that a 2-week combination treatment of 0.3 to 0.4 mg/kg of YM-254890 administered by intraperitoneal injection and 25 to 40 mg/kg linsitinib administered by oral gavage effectively inhibits the growth of metastatic UM tumors in immunodeficient NOD scid gamma (NSG) mice and identifies the IGF1 pathway as a potential resistance mechanism in response to Gαq/11 inhibition in UM. "
4.	Peripheral Arterial Disease 04/24/2006 - "These results suggest that the local administration of YM-254890 may be useful for treating peripheral arterial disease." 04/24/2006 - "Effect of YM-254890, a specific Galphaq/11 inhibitor, on experimental peripheral arterial disease in rats." 04/24/2006 - "The protective effect of YM-254890, a specific Galphaq/11 inhibitor, on laurate-induced peripheral arterial disease in rats was compared with those of prostaglandin E1 (PGE1), beraprost, and clopidogrel. "
5.	Neointima 07/01/2005 - "However, YM-254890 significantly reduced systemic blood pressure at doses 3 times higher than those that produced significant inhibitory effects on thrombosis and neointima formation. " 07/01/2005 - "Pharmacological properties of YM-254890, a specific G(alpha)q/11 inhibitor, on thrombosis and neointima formation in mice." 07/01/2005 - "Clopidogrel also significantly inhibited neointima formation at its antithrombotic dose, but its inhibitory potency was less than that of YM-254890. " 07/01/2005 - "Furthermore, oral administration of YM-254890 dose-dependently inhibited neointima formation 3 weeks after vascular injury with significant effects at 1 mg/kg twice daily for 1 week. " 07/01/2005 - "The pharmacological properties of YM-254890, a specific G(alpha)q/11 inhibitor, on acute thrombosis and chronic neointima formation after vascular injury have been investigated. "

Related Drugs and Biologics

1.	Tissue Plasminogen Activator (Alteplase)
2.	Phosphotransferases (Kinase)
3.	Dihydrotachysterol (AT 10)
4.	Proteins (Proteins, Gene)
5.	Small Interfering RNA (siRNA)
6.	Clopidogrel (Plavix)
7.	Calcium Chelating Agents
8.	Depsipeptides
9.	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)
10.	GTP-Binding Proteins (G-Protein)

Related Therapies and Procedures

1.	Intravenous Injections
2.	Intraperitoneal Injections
3.	Oral Administration